Blue Light Imaging (BLI) for Optical Diagnosis of Colorectal Polyps
BIRD
1 other identifier
observational
324
1 country
1
Brief Summary
Several imaging technologies have been developed in order to enable the endoscopists to differentiate neoplastic from non-neoplastic lesions. The real-time prediction of polyps histology is clinically relevant as diminutive polyps represent the majority of polyps detected during colonoscopy and have a very low risk of harboring advanced histology or invasive carcinoma. Thus, an optical diagnosis would allow diminutive polyps to be resected and discarded without pathological assessment or left in place without resection, with an enormous cost-saving potential. Recently, the American Society of Gastrointestinal Endoscopy (ASGE) has set the Preservation and Incorporation of Valuable endoscopic Innovation (PIVI) which defined accuracy threshold to be met, in order to consider a new technology ready to be incorporate into clinical practice. Blue Light Imaging (BLI) is a new chromoendoscopy technology integrated in the latest generation ELUXEOTM 7000 endoscopy platform (Fujifilm Co, Tokyo, Japan), based on the direct (i.e. not filtered) emission of blue light with short wavelength (410nm), that enhances visibility of both microvascular and superficial mucosal pattern. In a recent randomized trial BLI was superior to high-definition white light (HDWL) in the real time characterization of subcentimetric and diminutive colonic polyps. Nevertheless, in this study the paucity of diminutive rectosigmoid polyps analyzed does not allow to draw definite conclusions as the meeting of PIVI thresholds are concerned. Similarly, the low numbers of patients evaluated limited the per-patient analysis. Therefore further studies adequately powered to this clinically end-point were advocated. Additionally, when the study was performed a BLI dedicated classification for optical diagnosis of colonic polyps was not available, whereas recently a specific classification (the BLI Adenoma Serrated International Classification-BASIC) has been developed and a specific training set has been settled. In the present study the investigators prospectively evaluate whether the use of BLI-assisted optical characterization of diminutive polyps using BASIC classification by specifically trained endoscopists may met PIVI thresholds and particularly if it allow the endoscopists to achieve \> 90% correct assignment of post-polypectomy surveillance intervals when combined with the histopathology assessment of polyps \>5 mm in size.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 15, 2018
CompletedFirst Posted
Study publicly available on registry
November 19, 2018
CompletedStudy Start
First participant enrolled
January 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
October 30, 2019
CompletedMay 19, 2020
May 1, 2020
9 months
November 15, 2018
May 17, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Accuracy of post-polypectomy surveillance interval
Surveillance interval will be advised for each patient, basing on high-confidence predictions of \<5mm polyp histology. Such information will be merged with the histopathology assessment of both polyps \>5 mm in size and \<5 mm lesions diagnosed with a low confidence. Patients with either only \<5 mm lesions diagnosed with a low confidence or only \>6 mm lesions will not be included. Endoscopy-directed surveillance strategy will be subsequently matched with histology-directed one for each patient and accordance rate will be calculated. The post-polypectomy surveillance interval will be calculated in the frame of USMSTF guidelines.
9 months
Secondary Outcomes (2)
Accuracy parameters of BLI polyp characterization
9 months
Cost analysis
9 months
Study Arms (1)
Patients with rectosigmoid colonic polyps
Consecutive adult (18-80 yrs) outpatients undergoing colonoscopy in the frame of the FOBT based screening program, in which at least one diminutive (\<5 mm) rectosigmoid polyp is detected.
Interventions
All rectosigmoid \<5 mm polyps, regardless of the presence of larger polyps, will be characterized by BLI-assisted optical diagnosis by using BASIC criteria (neoplastic vs. non neoplastic) and will be included in polyp-level assessment. The polyp characterization will be always performed and recorded without zoom magnification. In patients in which colonoscopy will be performed with endoscopes equipped with zoom magnification, the zoom will be eventually systematically applied and the characterization with zoom will be also recorded. The post-polypectomy surveillance intervals based on BLI will be calculated by using histology estimation performed without zoom for all patients. Only polyps characterized with high confidence will be included in the analysis; the high-confidence characterization rate will be calculated.
Eligibility Criteria
Consecutive adult (18-80 yrs) outpatients undergoing colonoscopy in the frame of the FOBT based screening program or for CRC primary prevention, in which at least one diminutive (\<5 mm) rectosigmoid polyp is detected.
You may qualify if:
- Consecutive adult (18-80 yrs) outpatients undergoing colonoscopy in the frame of the FOBT based screening program or for CRC primary prevention, in which at least one diminutive (\<5 mm) rectosigmoid polyp is detected.
You may not qualify if:
- patients with CRC history or hereditary polyposis syndromes or hereditary non-polyposis colorectal cancer
- patients with inadequate bowel preparation
- patients in which caecal intubation was not achieved or scheduled for partial examinations
- polyps could not be resected due to ongoing anticoagulation preventing resection and pathologic assessment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Valduce Hospitallead
Study Sites (1)
Ospedale Valduce
Como, 22100, Italy
Related Publications (1)
Rondonotti E, Hassan C, Andrealli A, Paggi S, Amato A, Scaramella L, Repici A, Radaelli F. Clinical Validation of BASIC Classification for the Resect and Discard Strategy for Diminutive Colorectal Polyps. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2357-2365.e4. doi: 10.1016/j.cgh.2019.12.028. Epub 2020 Jan 7.
PMID: 31923641DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Franco Radaelli, MD
Valduce Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of Gastrointestinal Endoscopy Unit
Study Record Dates
First Submitted
November 15, 2018
First Posted
November 19, 2018
Study Start
January 1, 2019
Primary Completion
September 30, 2019
Study Completion
October 30, 2019
Last Updated
May 19, 2020
Record last verified: 2020-05